Sentiment for Atrion Corp (NASDAQ:ATRI)
Atrion Corp (NASDAQ:ATRI) institutional sentiment decreased to 0.89 in 2015 Q3. Its down -0.62, from 1.51 in 2015Q2. The ratio turned negative, as 56 institutional investors increased and opened new stock positions, while 37 sold and decreased stakes in Atrion Corp. The institutional investors in our partner’s database now own: 5.60 million shares, up from 964,071 shares in 2015Q2. Also, the number of institutional investors holding Atrion Corp in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 7 Reduced: 30 Increased: 40 New Position: 16.
Atrion Corporation develops and makes products primarily for medical applications. The company has a market cap of $701.93 million. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. It has 24.56 P/E ratio. The Company’s fluid delivery products include valves that promote infection control and needle safety.
About 1,041 shares traded hands. Atrion Corporation (NASDAQ:ATRI) has declined 4.98% since July 31, 2015 and is downtrending. It has underperformed by 0.12% the S&P500.
According to Zacks Investment Research, “ATRION CORP. AlaTenn is a diversified holding co. w/2 lines of business: energy - natural gas transmission and marketing, primarily through the provision of natural gas service in the lower Tennessee Valley area and the manufacture of products for the health care industry.”
Roberts Glore & Co Inc Il holds 1.97% of its portfolio in Atrion Corporation for 6,712 shares. Minerva Advisors Llc owns 4,698 shares or 1.24% of their US portfolio. Moreover, Thomson Horstmann & Bryant Inc has 1.14% invested in the company for 31,049 shares. The Wisconsin-based Morgan Dempsey Capital Management Llc has invested 1.04% in the stock. Aldebaran Financial Inc., a Tennessee-based fund reported 1,400 shares.#img1#
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
